Review
Biologic agents and approaches in the management of patients with lymphoma. A critical appraisal
Affiliations
- PMID: 1718939
Item in Clipboard
Review
Biologic agents and approaches in the management of patients with lymphoma. A critical appraisal
Hematol Oncol Clin North Am.
1991 Oct.
Abstract
There are many new approaches to cancer treatment emerging as a result of improvements in our understanding of tumor biology and the host response to cancer. At this time, none of these new approaches are sufficiently active or well developed to replace or improve upon standard combination chemotherapy in the management of patients with lymphoma.
Similar articles
-
[The role of biotherapy in multiple myeloma].Recenti Prog Med. 2000 Oct;91(10):488-93. Recenti Prog Med. 2000. PMID: 11072735 Review. Italian.
-
New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2.J Intraven Nurs. 1989 Mar-Apr;12(2):103-13. J Intraven Nurs. 1989. PMID: 2475596 Review.
-
Biological response modifiers: the new immunotherapy.Cancer Res. 1989 Apr 1;49(7):1621-39. Cancer Res. 1989. PMID: 2466558 Review. No abstract available.
-
Immunomodulators in the treatment of cutaneous lymphoma.J Eur Acad Dermatol Venereol. 1999 Sep;13(2):83-90. J Eur Acad Dermatol Venereol. 1999. PMID: 10568485 Review.
-
Therapeutic immunomodulation.Dermatol Clin. 1988 Oct;6(4):561-8. Dermatol Clin. 1988. PMID: 2465856 Review.
Cited by
-
Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma.Invest New Drugs. 1992 Nov;10(4):351-5. doi: 10.1007/BF00944195. Invest New Drugs. 1992. PMID: 1487412 Clinical Trial.
-
The role of interferon as maintenance therapy in malignant lymphoma.Med Oncol. 1997 Sep-Dec;14(3-4):153-7. doi: 10.1007/BF02989643. Med Oncol. 1997. PMID: 9468038 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical